Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide
- To evaluate the efficacy of a new induction regimen comprising ifosfamide in
combination with high-dose methotrexate, cisplatin, and doxorubicin hydrochloride, in
terms of clinical response and pathological response of the tumor, in patients with
newly diagnosed high-grade osteosarcoma.
- To determine the overall survival and disease-free survival of these patients.
- To evaluate the toxicity of this regimen.
- To correlate MRI imaging of the primary tumor with histopathologic grading after
treatment with this regimen.
OUTLINE: This is a multicenter study.
- Neoadjuvant chemotherapy (weeks 1-15): Patients receive ifosfamide IV over 1 hour on
days 1-5 and 36-40; doxorubicin hydrochloride IV over 18 hours on days 1-3 and 36-38
and IV over 72 hours on days 71-73; high-dose methotrexate IV over 4 hours on days 22,
29, 57, 64, 92, and 99; and cisplatin IV over 4 hours on day 71.
- Surgery (week 16): Patients undergo resection of the tumor on day 106. Patients found
to have unresectable disease are treated on an alternative protocol unless they have
clear clinical and pathologic response to treatment.
- Adjuvant chemotherapy (weeks 18-43): Beginning 2 weeks after surgery, patients receive
ifosfamide IV over 1 hour on days 120-124, 155-159, 225-229, and 260-264; doxorubicin
hydrochloride IV over 18 hours on days 120-122 and 155-157 and IV over 72 hours on days
190-192; high-dose methotrexate IV over 4 hours on days 141, 148, 176, 183, 211, 218,
246, 253, 281, and 288; and cisplatin IV over 4 hours on days 190 and 289.
After completion of study therapy, patients are followed every 2 months for 1 year, every 4
months for 2 years, every 6 months for 2 years, and then annually thereafter.
Primary Purpose: Treatment
Histopathologic response rate
Gerald S. Gilchrist, MD
United States: Federal Government